96 results about "Sphingomyelin" patented technology

The invention discloses a brain targeting liposome and the process for preparing brain targeting liposome pharmaceutical preparation, wherein the brain targeting liposome pharmaceutical preparation comprises medicament, various synthesized or natural phosphatide with brain targeting function as liposome coating material, cephalin having brain tissue absorption accelerating agent, liposome coating material, sphingomyelin with brain tropism and immunity activation, cholestrin for liposome coating material and liposome stabilizing agent, vitamin E as anti-oxidizing agent and polyoxyethylene glycols and phosphatide derivative for extending the half-decay time of liposome pharmaceutical blood.

The present disclosure provides a multi-metabolite platform using one or more metabolite selected from a group consisting of tryptophan, homoserine, fatty acid (16:1), fatty acid (18:0), fatty acid (18:1), fatty acid (18:2), fatty acid (22:6), phosphatidylcholine (PC) (34:2), PC (34:3), lysophosphatidylcholine (lysoPC) (16:0), lysoPC (18:0), lysoPC (20:3), lysoPC (20:4), lysoPC (22:6), monoglyceride (18:1/0:0/0:0) and sphingomyelin (d18:2/16:0) as a biomarker, which can diagnose acute coronary syndrome as well as the symptoms occurring prior to the onset of the disease simply and accurately through in-vivo level analysis.

The present invention is based on the idea of determining certain molecular lipids from a subject's blood sample, for example from serum or plasma sample, and based on the amounts of the determined lipids determining the amount of liver fat and/or diagnosing NAFLD in the subject. More specifically the subjects with elevated liver fat amount and NAFLD are characterized by elevated triglycerides with low carbon number and double bond content in the blood sample. Lysophosphatidylcholines, ether phospholipids, sphingomyelins and PUFA-containing phospholipids are diminished in the blood samples of subjects with an elevated liver fat amount and NAFLD. The method of the present invention can be further used for monitoring the subject's response to the treatment of NAFLD or to the treatment of lowering of the liver fat amount in the subject.

The present disclosure provides a composition and method for promoting functional neuronal development in pediatric subjects. The composition comprises in some embodiments up to about 7 g/100 Kcal of a fat or lipid source; up to about 5 g/100 Kcal of a protein source; about 3 mg/100 Kcal to about 50 mg/100 Kcal of phosphatidylethanolamine; about 0.15 mg/100 Kcal to about 75 mg/100 Kcal of sphingomyelin; and about 5 mg/100 Kcal to about 75 mg/100 Kcal of docosahexaenoic acid. The methods comprise, in some embodiments, administering the aforementioned composition to a pediatric subject.

An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.

Provided, among other things, is a delivery composition comprising: an aqueous carrier; a lipid component suspended in the carrier comprising significant amounts of type A lipid, fatty acid, and bilayer-stabilizing steroid(s), wherein type A lipid is one or more of any of phospholipid, ceramide(s) sphingomyelin(s) and glucocerebroside(s); and a bioactive agent, wherein (a) the delivery composition is packaged with a label with directions for mucosal, pulmonary or oral administration, and/or (b)(i) the viscosity of the composition is adjusted to a viscosity appropriate for spraying and/or (ii) the type A lipid comprises conjugate(s) of lipid-phase anchoring hydrophobic moieties and flexible, soluble polymers, and/or (iii) comprises a stabilizing effective amount of soluble polymers.

The invention discloses sheath fluid for a urine analyzer and a preparation method thereof, which belong to the technical field of sheath fluid. The technical problem that sheath fluid for a urine analyzer in the prior art contains an organic solvent and needs to be heated and dissolved is solved. The sheath fluid for the urine analyzer comprises water, an osmotic pressure compensating agent, a chelating agent, a surfactant, a particle stabilizer and an antibacterial agent, the pH range is 6-8, and the osmotic pressure range is 220-340 mOsm/kg; the particle stabilizer is one or more of sodiumhyaluronate, sphingomyelin, adenine, aprotinin, trehalose, glucose and the like, and in the sheath fluid, the mass concentration of the particle stabilizer is less than or equal to 4g/L. The sheath fluid for the urine analyzer can form sheath flow without changing the particle form, the corrosion to a detection device is small, and a sample wrapped by the sheath fluid not only enables the detection device to count particles, but also can be shot and imaged at a high speed.

The embodiment of the invention relates to infant formula milk powder rich in a milk fat globule membrane protein, phospholipid and oligosaccharide. The infant formula milk powder takes raw milk as araw material, and through formula adjustment, the content of bioactive substance MFGM-protein with special functional components, lactoferrin(LF), alpha-lactalbumin (alpha-La), total galactooligosaccharides(GOS), total polyfructose, sialic acid, total phospholipids, sphingomyelin(SM), lecithin (PC), phosphatidylserine(PS), phosphatidylethanolamine(PE), phosphatidylinositol(PI), ganglioside(Gang),triglyceride(TAG) and diglyceride( DAG ), is increased, the purpose of promoting field planting of probiotics in intestines flora of babies, particularly notably enriching lactic acid bacteria in intestines, reducing infectious microbes of unsorted bacteria families, increasing the content of immunological factors in the intestines and reducing the incidence rate of intestines diseases can be realized. The formula is suitable for development of formula milk powder for infants and large infants.

The invention discloses a freeze-drying protective agent for sphingomyelinase and a preparation method, and belongs to the technical field of biology. The freeze-drying protective agent of sphingomyelinase comprises the following components: 0.2%-0.3% (w/v) of cane sugar, 0.1%-0.4% (w/v) of trehalose, 0.2%-0.5% (w/v) of D-mannitol, 0.1%-0.4% (w/v) of glycine, 0.02%-0.05% (v/v) of Tween 20 and 5-10 mM of Mg<2+>. Through formula screening and optimization, the obtained sphingomyelinase freeze-dried powder has the characteristics of high enzyme activity, good thermal stability, long storage time and good appearance.

An agent for preventing infection of influenza virus or a food and drink for preventing infection of influenza virus is provided. The agent for preventing infection of influenza virus and food and drink for preventing infection of influenza virus containing a fat globule membrane component as an active ingredient. The agent for preventing infection of influenza virus and food and drink for preventing infection of influenza virus containing a phospholipid with sphingosine and/or a derivative thereof, particularly sphingomyelin as an active ingredient.

The invention provides a biomarker for diagnosing the working of nervonic acid supplemented for ischemic hypoxic encephalopathy and application of the biomarker. The biomarker comprises ceramide phosphate (d18: 1/24: 1(15Z)), and the ceramide phosphate is combined with any one selected from sphingomyelin (d18: 1/15: 0), docosapentaenoic acid, hexanoyl carnitine, phosphatidylcholine (22: 6(/20: 5) or 2-hydroxyhexadecanoylcarnitine to diagnose whether the nervonic acid supplemented for the ischemic-hypoxic encephalopathy takes effect or not. According to the biomarker for diagnosing the working of nervonic acid supplemented for ischemic hypoxic encephalopathy, by detecting the biomarker, whether nervonic acid is absorbed and transformed by a body suffering from the ischemic hypoxic encephalopathy or not can be judged, and guiding significance is provided for judging whether acer truncatum bunge nervonic acid oil or similar products have effects or not when the acer truncatum bunge nervonic acid oil or similar products are taken by patients with the ischemic hypoxic encephalopathy.

The invention relates to a hydrothorax exosome metabolite combination, a kit and a method for diagnosing tuberculous pleurisy. The hydrothorax exosome metabolite combination for diagnosing the tuberculous pleurisy is prepared from dimethylglycine, choline, acyl carnitine with the ratio of 10: 2, phosphatidylcholine with the ratio of 35: 6, phosphatidylcholine o with the ratio of -36: 0, phosphatidylethanolamine with the ratio of 33: 2, sphingomyelin with the ratio of 28: 1 and oleic acid. The kit for diagnosing the tuberculous pleurisy comprises an internal standard substance required for detecting the concentration of the metabolites in the hydrothorax exosome sample extraction solution. A combined marker provided by the invention has the characteristics of high sensitivity and high specificity for the diagnosis of tuberculous pleurisy, and meanwhile, can be complementary with the traditional marker adenosine deaminase, and can be used for the auxiliary diagnosis of the tuberculous pleurisy by being combined with the traditional marker adenosine deaminase.

An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition, in which liposomes encapsulate a drug, with a platinum preparation. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) a platinum preparation, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin; and cholesterols, the liposome composition includes a drug and has an inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the platinum preparation are administered simultaneously or sequentially.